Editas Medicine Inc
Company Profile
Business description
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Contact
11 Hurley Street
CambridgeMA02141
USAT: +1 617 401-9000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
226
Stocks News & Analysis
stocks
The best way to get rich and retire early
stocks
Investors overly negative on cheap ASX share
stocks
Overvalued US AI play reports earnings
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,073.90 | 55.30 | 0.61% |
| CAC 40 | 8,121.07 | 0.00 | 0.00% |
| DAX 40 | 24,283.97 | 4.43 | -0.02% |
| Dow JONES (US) | 48,362.68 | 227.79 | 0.47% |
| FTSE 100 | 9,865.97 | 31.45 | -0.32% |
| HKSE | 25,834.28 | 32.51 | 0.13% |
| NASDAQ | 23,428.83 | 121.21 | 0.52% |
| Nikkei 225 | 50,480.06 | 77.67 | 0.15% |
| NZX 50 Index | 13,516.13 | 7.83 | 0.06% |
| S&P 500 | 6,878.49 | 43.99 | 0.64% |
| S&P/ASX 200 | 8,774.70 | 57.80 | 0.66% |
| SSE Composite Index | 3,922.45 | 5.09 | 0.13% |